Verix boosts life science AI capabilities with start-up.ai acquisition

Artificial intelligence (AI)-driven commercial optimisation platform provider Verix has purchased start-up.ai for an undisclosed sum, boosting its life science AI capabilities.

start-up.ai is a group of AI specialists that helps enterprises improve their processes through AI and machine learning.

The company will be merged with Verix’s AI lab, and start-up.ai co-founder and CEO Shahar Cohen will become Verix’s CTO.

The deal enables Verix to further improve its capacities to use AI to advance the brand growth of life science companies.

Pharmaceutical firms usually depend upon consulting analytical services for marketing and sales decisions related to their strategy and execution. This is a time-consuming and costly process.

Verix states that it leverages AI to provide more in-depth, precise data on the market more quickly and at a lower cost.

The company also uses anonymised drug prescription data from healthcare professionals (HCPs) and multiple data sets such as lab data, digital marketing information and demographics to help pharma firms optimise the processes related to their business.

Using these data, pharma firms can also ensure that the right medicines will be available to the right patients at the right time.

Verix CEO Doron Aspitz stated: “In our time working with start-up.ai, we were consistently impressed with their AI capabilities and innovative approach to solving customer challenges.

“As we continue to grow, serving more and more customers, we understand the strategic value of continuing to build out category-leading AI capabilities, which are embedded in Tovana, our opportunity engine platform.

“Adding the start-up.ai team to Verix was a natural decision for us and we are excited about what our new capabilities will enable us to deliver to our customers and partners around the world.”